GeneDx Holdings Corp. Hit With Federal Securities Class Action, Law Firm Tells Investors to Act

DJS Law Group has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), alleging the company violated federal securities statutes that prohibit fraudulent conduct in connection with the purchase or sale of securities. The Los Angeles-based law firm announced the litigation on June 29, 2026, and is urging affected investors to come forward.

The Legal Claims

The complaint targets GeneDx under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as Rule 10b-5 promulgated under that statute. Section 10(b) and Rule 10b-5 are the principal antifraud provisions of federal securities law, prohibiting material misstatements or omissions made in connection with securities transactions. Section 20(a) extends liability to controlling persons — typically executives or directors — who are found to have directed or participated in a primary violation.

Together, the provisions form the standard foundation for securities fraud class actions brought on behalf of shareholders who allege they were harmed by misleading corporate disclosures.

What Investors Are Being Told

DJS Law Group is alerting GeneDx investors to the pending action and encouraging those who believe they suffered losses to contact the firm to discuss their rights. Class actions of this type allow groups of similarly situated shareholders to pursue claims collectively, a structure that lowers the individual barrier to litigation in cases involving publicly traded companies.

GeneDx Holdings Corp. trades on the Nasdaq exchange under the ticker symbol WGS. The source does not specify the class period, the nature of the alleged misrepresentations, or the claimed damages.

What Comes Next

Securities class actions proceed through defined stages — lead plaintiff appointment, motion to dismiss, discovery, and, if the case survives, potential settlement or trial. The filing of a complaint is the earliest stage; courts have regularly dismissed such suits at the motion-to-dismiss phase, and litigation outcomes vary widely.

The source provides no statement from GeneDx or its representatives. The company had not responded publicly as of the announcement date.